Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond James in a research report issued to clients and investors on ...

Insulet Co. (NASDAQ:PODD – Get Free Report)’s share price gapped down before the market opened on Friday . The stock had previously closed at $288.29, but opened at $276.35. Insulet shares last traded ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category. Insulet faces significant business and financial risks ...

Morgan Stanley raised the firm’s price target on Insulet (PODD) to $325 from $317 and keeps an Overweight rating on the shares following a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?